CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer have?

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer has 56 citations in the OpenAlex counts ScholarIQ stores.

When was CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer published?

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer has 2015 year in the ScholarIQ index.

What is the open-access status of CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer has closed oa status in the ScholarIQ index.

What is the DOI of CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?

The DOI for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is on the source record.

What is the PMID of CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?

The PMID for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is on the source record.

What is the OpenAlex record for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?

The OpenAlex for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is on the source record.